• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Alvotech

    11/6/24 1:51:59 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALVO alert in real time by email
    SC 13G/A 1 tm2427411d1_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    AMENDMENT NO. 1 TO SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    Alvotech

    (Name of Issuer)

     

     

    Ordinary Shares, with nominal value of $0.01 per share

    (Title of Class of Securities)

     

    L01800108

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event, which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨       Rule 13d-1(b)

    x      Rule 13d-1(c)

    ¨       Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information, which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act out shall be subject to all other provisions of the Act, (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. L01800108

     

      1. Names of Reporting Persons.
        I.R.S. Identification Nos. of above persons (entities only)
         
    YA II PN, Ltd.
    (98-0615462)
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  x
        (b)  ¨
         
      3. SEC Use Only
         
      4. Citizenship or Place of Organization:  Cayman Islands
         

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

    5. Sole Voting Power: 0
         
         
    6 Shared Voting Power: 0
         
         
    7. Sole Dispositive Power: 0
         
         
    8. Shared Dispositive Power: 0
         

      9. Aggregate Amount Beneficially Owned by Each Reporting Person:   0
         
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
         
      11. Percentage of Class Represented by Amount in Row (9):        0%
         
      12. Type of Reporting Person (See Instructions):     OO

     

     

     

     

    CUSIP No. L01800108

     

      1. Names of Reporting Persons.
        I.R.S. Identification Nos. of above persons (entities only)
         
    YA Global Investments II (U.S.), LP
         
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  x
        (b)  ¨
         
      3. SEC Use Only
         
      4. Citizenship or Place of Organization:  Delaware
         

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

    5. Sole Voting Power: 0
         
         
    6 Shared Voting Power: 0
         
         
    7. Sole Dispositive Power: 0
         
         
    8. Shared Dispositive Power: 0
         

      9. Aggregate Amount Beneficially Owned by Each Reporting Person:  0
         
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
         
      11. Percentage of Class Represented by Amount in Row (9):         0%
         
      12. Type of Reporting Person (See Instructions):     OO

     

     

     

     

    CUSIP No. L01800108

     

      1. Names of Reporting Persons.
        I.R.S. Identification Nos. of above persons (entities only)
         
    Yorkville Advisors Global, LP
       
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  x
        (b)  ¨
         
      3. SEC Use Only
         
      4. Citizenship or Place of Organization:  Delaware
         

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

    5. Sole Voting Power: 0
         
         
    6 Shared Voting Power: 0
         
         
    7. Sole Dispositive Power: 0
         
         
    8. Shared Dispositive Power: 0
         

      9. Aggregate Amount Beneficially Owned by Each Reporting Person:  0
         
      10. Check if the Aggregate Amount in Row (9)  Excludes Certain Shares (See Instructions) ¨
         
      11. Percentage of Class Represented by Amount in Row (9):         0%
         
      12. Type of Reporting Person (See Instructions):     OO

     

     

     

     

    CUSIP No. L01800108

     

      1. Names of Reporting Persons.
        I.R.S. Identification Nos. of above persons (entities only)
         
    Yorkville Advisors Global II, LLC
         
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  x
        (b)  ¨
         
      3. SEC Use Only
         
      4. Citizenship or Place of Organization:  Delaware
         

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

    5. Sole Voting Power: 0
         
         
    6 Shared Voting Power: 0
         
         
    7. Sole Dispositive Power: 0
         
         
    8. Shared Dispositive Power: 0
         

      9. Aggregate Amount Beneficially Owned by Each Reporting Person:   0
         
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
         
      11. Percentage of Class Represented by Amount in Row (9):         0%
         
      12. Type of Reporting Person (See Instructions):     OO

     

     

     

     

    CUSIP No. L01800108

     

      1. Names of Reporting Persons.
        I.R.S. Identification Nos. of above persons (entities only)
         
    YAII GP, LP
         
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  x
        (b)  ¨
         
      3. SEC Use Only
         
      4. Citizenship or Place of Organization:  Delaware
         

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

    5. Sole Voting Power: 0
         
         
    6 Shared Voting Power: 0
         
         
    7. Sole Dispositive Power: 0
         
         
    8. Shared Dispositive Power: 0
         

      9. Aggregate Amount Beneficially Owned by Each Reporting Person:   0
         
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
         
      11. Percentage of Class Represented by Amount in Row (9):         0%
         
      12. Type of Reporting Person (See Instructions):     OO

     

     

     

     

    CUSIP No. L01800108

     

      1. Names of Reporting Persons.
        I.R.S. Identification Nos. of above persons (entities only)
         
    YAII GP II, LLC
         
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  x
        (b)  ¨
         
      3. SEC Use Only
         
      4. Citizenship or Place of Organization:  Delaware
         

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

    5. Sole Voting Power: 0
         
         
    6 Shared Voting Power: 0
         
         
    7. Sole Dispositive Power: 0
         
         
    8. Shared Dispositive Power: 0
         

      9. Aggregate Amount Beneficially Owned by Each Reporting Person:   0
         
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
         
      11. Percentage of Class Represented by Amount in Row (9):         0%
         
      12. Type of Reporting Person (See Instructions):     OO

     

     

     

     

    CUSIP No. L01800108

     

      1. Names of Reporting Persons.
        I.R.S. Identification Nos. of above persons (entities only)
         
    Mark Angelo
         
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  x
        (b)  ¨
         
      3. SEC Use Only
         
      4. Citizenship or Place of Organization:  United States
         

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

    5. Sole Voting Power: 0
         
         
    6 Shared Voting Power: 0
         
         
    7. Sole Dispositive Power: 0
         
         
    8. Shared Dispositive Power: 0
         

      9. Aggregate Amount Beneficially Owned by Each Reporting Person:  0
         
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
         
      11. Percentage of Class Represented by Amount in Row (9):         0%
         
      12. Type of Reporting Person (See Instructions):     OO

     

     

     

     

    CUSIP No. L01800108

     

      1. Names of Reporting Persons.
        I.R.S. Identification Nos. of above persons (entities only)
         
    SC-Sigma Global Partners, LP
    84-5173620
         
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  x
        (b)  ¨
         
      3. SEC Use Only
         
      4. Citizenship or Place of Organization:  Delaware
         

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

    5. Sole Voting Power: 0
         
         
    6 Shared Voting Power: 0
         
         
    7. Sole Dispositive Power: 0
         
         
    8. Shared Dispositive Power: 0
         

      9. Aggregate Amount Beneficially Owned by Each Reporting Person:  0
         
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
         
      11. Percentage of Class Represented by Amount in Row (9):         0%
         
      12. Type of Reporting Person (See Instructions):     OO

     

     

     

     

    This Amendment No. 1 is being filed by YA II PN, Ltd., YA Global Investments II (U.S.), Ltd., Yorkville Advisors Global, LP, Yorkville Advisors Global II, LLC, YA II GP, LP, YAII GP II, LLC and SC-Sigma Global Partners, LP (collectively, the “Reporting Persons”) and amends, supplements and supersedes, the initial Schedule 13G filed jointly by the Reporting Persons on February 14, 2023. This Amendment No. 1 is the final amendment to the Schedule 13G and constitutes an exit filing for the Reporting Persons.

     

    Item 1.

     

      (a) Name of Issuer:

     

    Alvotech

     

      (b) Address of Issuer’s Principal Executive Offices:

     

    9, Rue de Bitbourg

    Luxembourg, Luxembourg L-1273

     

    Item 2. Identity and Background.

     

      (a) Name of Person Filing:

     

    YA II PN, Ltd.

     

      (b) Address of Principal Executive Office or, if none, Residence of Reporting Persons:

     

    1012 Springfield Ave.

    Mountainside, NJ 07092

     

      (c) Citizenship:

     

    Cayman Islands

     

      (d) Title of Class of Securities:

     

    Ordinary Shares, with nominal value of $0.01 per share

     

      (e) CUSIP Number:

     

    L01800108

     

    Item 3. If the statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is:

     

    (a) ¨  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b) ¨  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c) ¨  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d) ¨  Investment company registered under section 8 of the Investment Company Act of 1940 (15 of the Act (15 U.S.C. 78o);
    (e) ¨  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f) ¨  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g) ¨  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
    (h) ¨  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) ¨  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) ¨  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J); or
    (k) x  Group, in accordance with 240.13d(b)(1)(ii)(K).

     

     

     

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

     

      (a) Amount beneficially owned: 0

     

      (b) Percentage of Class: 0%

     

      (c) Number of shares as to which the person has:

     

      (i) Sole Power to vote or to direct the vote: 0

     

      (ii) Shared power to vote or to direct the vote: 0

     

      (iii) Sole power to dispose or to direct the disposition: 0

     

      (iv) Shared power to dispose or to direct the disposition: 0

     

    Item 5. Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

     

    Item 6. Ownership of more than five percent on Behalf of Another Person.

     

    Not Applicable

     

     

     

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    Not Applicable

     

    Item 8. Identification and Classification of Member Group

     

    YA II PN, Ltd. (“YA II”) is beneficially owned by YA Global Investments II (U.S.), LP (the “YA Feeder”). Yorkville Advisors Global, LP (the “YA Advisor”) is the investment manager to YA II. Yorkville Advisors Global II, LLC (the “YA Advisor GP”) is the general partner to the YA Advisor. YAII GP, LP (the “YA GP”) is the general partner to the YA Feeder. YAII GP II, LLC (the “Yorkville GP”) is the general partner to the YA GP. Mark Angelo makes the investment decisions on behalf of YA II. Accordingly, each of YA II, YA Feeder, the YA Advisor, the YA Advisor GP, the YA GP, the Yorkville GP and Mark Angelo may be deemed affiliates and therefore may be deemed to beneficially own the same number of Class A Shares.

     

    YAII GP, LP is the general partner of SC-Sigma Global Partners, LP (“SC-Sigma”), which is an investor in YA II. YAII GP II, LLC is the general partner of YAII GP, LP. The YA Advisor is the investment manager to SC-Sigma. Accordingly, SC-Sigma, the YA GP, the Yorkville GP, the YA Advisor, and Mark Angelo may be deemed affiliates and therefore may be deemed to beneficially own the same number of shares of Class A Shares. 

     

    For purposes of this filing, each of the reporting persons is deemed an affiliate of each other reporting person.

     

    Item 9. Notice of Dissolution of Group

     

    Not Applicable

     

    Item 10. Certification

     

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as participant in any transaction having that purpose or effect.

     

    Additional Information:

     

    Each Reporting Person disclaims beneficial ownership of any securities beneficially owned by each other Reporting Person, and its report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of these securities for the purpose of Section 16 or for any other purpose.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement in true, complete and correct.

     

      REPORTING PERSON:  
         
    Dated: November 6, 2024  
     
      REPORTING PERSON:
     
    YA II PN, Ltd.  
       
    By: /s/ Robert Munro  
      Robert Munro  
      Chief Compliance Officer  
       
    YA Global Investments II (U.S.), LP  
       
    By: /s/ Robert Munro  
      Robert Munro  
      Chief Compliance Officer  
       
    Yorkville Advisors Global, LP  
       
    By: Yorkville Advisors Global, LLC  
    Its: General Partner  
       
    By: /s/ Robert Munro  
      Robert Munro  
      Chief Compliance Officer  
       
    Yorkville Advisors Global II, LLC  
       
    By: /s/ Robert Munro  
      Robert Munro  
      Chief Compliance Officer  
       
    YAII GP, LP  
       
    By: YAII GP II, LLC  
    Its: General Partner  
       
    By: /s/ Robert Munro  
      Robert Munro  
      Chief Compliance Officer  

     

     

     

     

    YAII GP II, LLC  
       
    By: /s/ Robert Munro  
      Robert Munro  
      Chief Compliance Officer  

     

    SC-Sigma Global Partners, LP  
       
    By: /s/ Robert Munro  
      Robert Munro  
      Chief Compliance Officer  

     

     

     

    Get the next $ALVO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALVO

    DatePrice TargetRatingAnalyst
    11/4/2025$8.00Buy → Hold
    Deutsche Bank
    10/14/2025$14.00Equal-Weight → Overweight
    Morgan Stanley
    9/23/2025$14.00Hold → Buy
    Deutsche Bank
    2/14/2025$18.00Buy
    UBS
    1/29/2024$10.00 → $17.00Equal Weight → Overweight
    Barclays
    10/20/2023$5.00 → $10.00Sell → Neutral
    Citigroup
    9/21/2023$10.00Equal Weight
    Barclays
    9/7/2022$10.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $ALVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alvotech downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded Alvotech from Buy to Hold and set a new price target of $8.00

    11/4/25 7:41:39 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alvotech upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Alvotech from Equal-Weight to Overweight and set a new price target of $14.00

    10/14/25 8:33:59 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alvotech upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded Alvotech from Hold to Buy and set a new price target of $14.00

    9/23/25 8:10:17 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALVO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update

    Total revenues in the first nine months of the year were $420 million, a 24% increase from the same period last year Product and service revenue increased by 85%, to $237 million in the first nine months compared to the same period last yearLicense and other revenue decreased by 13% to $182 million, compared to the same period last yearAdjusted EBITDA in the first nine months of the year was $68 million, a 21% decrease from the same period last year, driven by higher R&D investments to accelerate pipeline expansion and lower licensing revenues in the period. Phasing of revenues in 2024 resulted in Q2 being the best quarter of the year, while Q4 of is expected to be the best quarter of 2025  

    11/12/25 4:40:00 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)

    REYKJAVIK, Iceland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the outcome of expedited infringement proceedings before the UK High Court by Regeneron Pharmaceuticals Inc. ("Regeneron") and Bayer AG ("Bayer") against Alvotech and its contract manufacturing organization (CMO) in the United Kingdom. The court rejected Regeneron's and Bayer's injunction request in relation to manufacturing activities at Alvotech's CMO in the UK for Alvotech's biosimilar to Eylea® (AVT06). The decision will support commercial launches of Alvotech's biosimilar i

    11/10/25 4:00:00 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA

    REYKJAVIK, Iceland and LONDON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited ("Advanz Pharma"), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisations for all four presentations of Gobivaz®, Alvotech's biosimilar to Simponi® (golimumab). The authorisations cover Gobivaz® 50 mg/0.5 mL and 100 mg/mL presentations in both pre-fill

    11/6/25 9:07:08 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALVO
    SEC Filings

    View All

    SEC Form 6-K filed by Alvotech

    6-K - Alvotech (0001898416) (Filer)

    11/12/25 5:12:55 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Alvotech

    6-K - Alvotech (0001898416) (Filer)

    11/6/25 10:47:18 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Alvotech

    6-K - Alvotech (0001898416) (Filer)

    11/3/25 6:11:11 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALVO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SELARSDI issued to ALVOTECH USA INC

    Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-2) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

    10/21/24 10:44:05 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SELARSDI issued to ALVOTECH USA INC

    Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-1) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

    10/21/24 2:59:28 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SELARSDI issued to ALVOTECH USA INC

    Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-3) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

    10/21/24 2:59:28 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALVO
    Leadership Updates

    Live Leadership Updates

    View All

    Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia

    REYKJAVIK, ICELAND (August 20, 2025) — Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Patrik Ling has joined the company as VP Investor Relations Scandinavia, based in Stockholm. Patrik Ling has more than 25 years of experience in the life-science industry. Most recently he served as Senior Equity Analyst at the investment bank DNB Carnegie, covering life science companies, including Alvotech. He began his career in marketing and sales of pharmaceuticals, before transitioning to the financial sector, where he was a portfolio manager and equity analyst focusing on the life-s

    8/20/25 6:05:00 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer

    REYKJAVIK, ICELAND (July 10, 2025) — Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of Linda Jónsdóttir as Chief Financial Officer (CFO). Linda is a highly experienced international executive with a strong background in finance and corporate leadership. She has held senior roles across a range of industries, including banking, food technology, transportation, and healthcare. Linda will be based in Iceland. Joel Morales, who has served as CFO of Alvotech since 2020, based in the U.S., has decided to step down to spend more time in the U.S. and prioritize time with

    7/10/25 4:40:00 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer

    REYKJAVIK, Iceland, March 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, or the "Company")), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of Dr. Balaji V. Prasad as Chief Strategy Officer. A medical doctor by training, Dr. Prasad has 25 years' experience in the pharmaceutical industry, first as a consultant and subsequently as a financial and equities analyst focused on the specialty pharma and healthcare sectors. He was most recently a director and highly ranked equities analyst at Barclays, covering US specialty pharma and with Alvotech in his portfolio. He served previously

    3/27/25 4:30:00 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALVO
    Financials

    Live finance-specific insights

    View All

    Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update

    Total revenues in the first nine months of the year were $420 million, a 24% increase from the same period last year Product and service revenue increased by 85%, to $237 million in the first nine months compared to the same period last yearLicense and other revenue decreased by 13% to $182 million, compared to the same period last yearAdjusted EBITDA in the first nine months of the year was $68 million, a 21% decrease from the same period last year, driven by higher R&D investments to accelerate pipeline expansion and lower licensing revenues in the period. Phasing of revenues in 2024 resulted in Q2 being the best quarter of the year, while Q4 of is expected to be the best quarter of 2025  

    11/12/25 4:40:00 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update

    REYKJAVIK, Iceland, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first nine months of the year ended September 30, 2025, after U.S. markets close on Wednesday, November 12, 2025. Alvotech will also conduct a conference call to present the financial results on Thursday November 13, 2025, at 8:00 am EST (13:00 GMT, 14:00 CET). On the call, management will provide a business update, including the status of pending approvals in the U.S. and Europe. A call in number is available for participants in the

    11/4/25 4:01:00 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT

    REYKJAVIK, Iceland, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first half of the year ended June 30, 2025, after U.S. markets close on Wednesday, August 13, 2025. Alvotech will also conduct a conference call to present the financial results and recent business highlights on Thursday, August 14, 2025, at 8:00 am EDT (12:00 noon GMT, 14:00 CET). Live audio of the conference call will be webcast and available on Alvotech's investor portal.   Information on how to access the webcast or particip

    8/6/25 8:00:00 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Alvotech

    SC 13G/A - Alvotech (0001898416) (Subject)

    11/6/24 1:51:59 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Alvotech

    SC 13D/A - Alvotech (0001898416) (Subject)

    7/3/24 5:31:12 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Alvotech (Amendment)

    SC 13G/A - Alvotech (0001898416) (Subject)

    2/14/24 12:14:38 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care